Health-care products maker Johnson & Johnson won US approval to sell a new HIV drug called Intelence for patients with resistance to other therapies, US officials said on Friday. The drug, also known as TMC125 or etravirine, is a new member of the family of AIDS-fighting drugs called non-nucleoside reverse transcriptase inhibitors (NNRTI).
More than two dozen drugs are approved for fighting the deadly HIV virus. Patients need new options because HIV can mutate to resist existing treatments.